A5020418022- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Treatments and Mutations
- Cancer-related gene regulation
- Esophageal and GI Pathology
- Bone Metabolism and Diseases
- ECG Monitoring and Analysis
- Epigenetics and DNA Methylation
- Metabolism, Diabetes, and Cancer
- Inflammatory Biomarkers in Disease Prognosis
- RNA Research and Splicing
- Colorectal Cancer Screening and Detection
- Extracellular vesicles in disease
- Colorectal Cancer Treatments and Studies
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Growth Hormone and Insulin-like Growth Factors
- BRCA gene mutations in cancer
- Molecular Biology Techniques and Applications
- Cancer-related Molecular Pathways
- Digestive system and related health
Istituto Oncologico Veneto
2013-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2024
University of Padua
2016
Reha Rheinfelden
2016
Yamagata Research Institute Of Technology
2016
PharmacoGenetics (China)
2013
Objective At present, no consensus exists on the beneficial effect of preoperative cisplatin/5-fluorouracil (5-FU)-based chemotherapy versus primary surgery in management patients with esophageal cancer. The aim this study was to evaluate impact some relevant genetic polymorphisms, within drug-related and DNA repair genes, clinical outcome cancer subjected cisplatin/5-FU-based neoadjuvant treatment. Methods from 143 patients, 63 receiving therapy 80 surgery, analyzed for following...
Background Development of novel therapeutic drugs and regimens for cancer treatment has led to improvements in patient long-term survival. This success has, however, been accompanied by the increased occurrence second primary cancers. Indeed, patients who received regional radiotherapy Hodgkin's Lymphoma (HL) or breast may develop, many years later, a solid metachronous tumor irradiated field. Despite extensive epidemiological studies, little information is available on genetic changes...
DNA methylation plays an important role in cancer development. Cancer cells exhibit two types of alteration: site-specific hypermethylation at promoter oncosuppressor genes and global hypomethylation. This study evaluated the patterns long interspersed nuclear element (LINE-1) sequences which, due to their relative abundance genome, are considered a good surrogate indicator methylation. LINE-1 status was investigated cell-free (cfDNA) 21 patients, 19 with esophageal adenocarcinoma (EADC) 2...
Anti-HER2 monoclonal antibody trastuzumab improves the survival of those patients with advanced gastroesophageal adenocarcinoma (GEA) exhibiting HER2/ERBB2 overexpression/amplification. The current gold standard methods used to diagnose HER2 status in GEA are immunohistochemistry (IHC) and silver or fluorescence situ hybridization (SISH FISH). However, they do not permit spatial temporal tumor monitoring, nor overcome intra-cancer heterogeneity. Droplet digital PCR (ddPCR) was implement...
Gastroesophageal adenocarcinoma (GEA) patients with the microsatellite instability (MSI) subtype emerged as optimal candidates for immunotherapy. To date, immunohistochemistry (IHC) is gold standard MSI assessment in formalin-fixed paraffin-embedded (FFPE) specimens. However, IHC, although useful diagnostic typing, cannot be used to analyze cell-free DNA (cfDNA) liquid biopsy, a tool that could overcome tumor heterogeneity and enable longitudinal monitoring. In order find an alternative...
Liquid biopsy is currently approved for management of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients. However, one unanswered question whether the rate cell-free DNA (cfDNA)-negative samples due to technical limitations rather than tumor genetic characteristics. Using four microsatellite markers that map specific chromosomal loci often lost in cancer, we conducted a pilot study investigate other alterations, such as loss heterozygosity (LOH),...
Esophageal cancer (EC) is a very aggressive tumor, and no reliable prognostic markers exist especially for resectable advanced neoplasia. The principal aim of this study was to investigate the association germline polymorphisms in nucleotide excision repair (NER) pathway genes with overall survival (OS) patients EC. As second aim, we also studied NER gene variants response cisplatin-based chemotherapy. Among EC referred our Institution between 2004 2012, selected cohort 180 diagnosed...
Chromosomal instability (CIN) is very frequent in gastroesophageal adenocarcinoma (GEA) and it characterized by TP53 deletions/mutations resulting p53 nuclear accumulation, as revealed immunohistochemistry (IHC), which considers the cases with “high” staining levels to be positive. Aiming improve aberrant detection, droplet digital PCR (ddPCR) was used evaluate deletion formalin-fixed, paraffin-embedded DNA (FFPE-DNA) cell-free (cfDNA). To further investigate mutational profile,...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited survival. Curative opportunities are only available for patients resectable cancer. Palliative chemotherapy the current standard of care unresectable tumors. Numerous efforts have been made to investigate new therapeutic strategies PDAC. Immunotherapy has found be effective in treating tumors high microsatellite instability (MSI-H), including The ability Endoscopic Ultrasound Fine Needle Biopsy (EUS-FNB)...
<title>Abstract</title> Esophageal and esophagogastric junction adenocarcinoma (EADC-EGJA) prognosis is poor, Barrett’s esophagus has increased risk of developing tumor through the carcinogenesis process from metaplasia/low-grade dysplasia to high-grade (HGD). Long interspersed nuclear element-1 (LINE-1) considered a surrogate marker global methylation, an epigenetic event contributing progression. cfDNA 90 patients with never dysplastic (NDBE), HGD/early EADC-EGJA or locally...
Several chronic diseases have been associated with bone alteration in the last few years. Despite wealth of information provided by analysis transcriptome affected tissues, only a limited number studies evaluated gene expression tissue due to difficulty obtain high quality RNA. Therefore, skeletal pathologies often defective maturation process that occurs during recruitment progenitor stem cells. In order explore possibility analysing osteogenic differentiation tissue, single-step method...
Esophageal cancer (EC) is a highly aggressive tumor, and the current monitoring procedures are partially inadequate to evaluate treatment efficacy. The aim of this study was investigate whether allelic imbalance analysis in liquid biopsy could be used as an additional tool monitor tumor burden EC patients. For purpose, circulating cell-free DNA (cfDNA) from 52 patients with locally advanced EC, which underwent neoadjuvant resection, analyzed. Data four representative longitudinally followed...
Aim: Clinical features of esophageal cancer (EC) patients have poor prognostic power. Thus, it is paramount to discover biomarkers that can allow a more accurate survival prediction. Methods: To detect genetic variants associated with survival, DNA from 120 treated cisplatin-based neoadjuvant therapy were genotyped using drug metabolism enzymes and transporters array. Results: We identified two variants: the rs2038067 in PPARD (p = 0.0004) rs683369 (F160L) SLC22A1 0.001). Their power was...